Tanios S. Bekaii-Saab, MD, on Next-Generation Sequencing for Gastrointestinal Cancer

Video

The medical oncologist spoke about the need to make next-generation sequencing available to all patients with gastrointestinal cancer.

Next-generation sequencing has revolutionized genomic research, helping oncologists to deliver the proper treatment to the proper target, thereby improving outcomes.

Specifically for patients with gastrointestinal cancers, precision therapy has represented a paradigm shift in the way oncologists approach patient care.

In an interview with CancerNetwork®, Tanios S. Bekaii-Saab, MD, a medical oncologist at the Mayo Clinic in Phoenix, Arizona, discussed why next-generation sequencing is so important for patients with gastrointestinal cancers, as well as the need to make genomic sequencing the standard of care for this entire patient population.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Related Content
SIR-Sphere Y-90 resin microspheres are the only approved radioembolization treatments in the US for both HCC and mCRC.

FDA Approves SIR-Sphere Y-90 in HCC

Ariana Pelosci
July 7th 2025
Article

SIR-Sphere Y-90 resin microspheres are the only approved radioembolization treatments in the US for both HCC and mCRC.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Investigators will present detailed results from the phase 3 FORTITUDE-101 trial at a future medical meeting.

Bemarituzumab Regimen Improves Survival in FGFR2b+ Gastric/GEJ Cancer

Russ Conroy
July 3rd 2025
Article

Investigators will present detailed results from the phase 3 FORTITUDE-101 trial at a future medical meeting.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Exercise-Based Regimen Shows Efficacy Promise in CRC

Exercise-Based Regimen Shows Efficacy Promise in CRC

Ariana Pelosci
June 30th 2025
Article

Nicholas J. Hornstein, MD, PhD, highlighted results from the phase 3 ATOMIC and CHALLENGE trials in CRC presented at the 2025 ASCO Annual Meeting.

Data from part B of the DeFianCe study demonstrate a positive overall response rate trend with sirexatamab plus bevacizumab and chemotherapy.

Sirexatamab Combo Significantly Improves PFS in MSS CRC Subgroups

Russ Conroy
June 28th 2025
Article

Data from part B of the DeFianCe study demonstrate a positive overall response rate trend with sirexatamab plus bevacizumab and chemotherapy.